drugset
drugset / Trial / NCT05228119

A Study of Oncolytic Virus Injection (RT-01) in Combination With PD-1 Inhibitor in Patients With Advanced Solid Tumors

NCT05228119 ↗

Phase 1 Unknown 50 enrolled The Affiliated Hospital of Xuzhou Medical University
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of oncolytic virus injection(RT-01) in combination with PD-1 inhibitor (Nivolumab) in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity, The immunoreactivity, The immunogenicity, pharmacokinetics and virus shedding of RT-01 in combination with PD-1 inhibitor.

Timeline

Start
2022-01-04
Primary completion
2022-10-01
Completion
2023-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody — Intravenous
Subject RT-01 Other / unclassified — Intravenous

Indications

neoplasm